Reviewing the Significance of Blood–Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The disruption of blood–brain barrier (BBB) for multiple sclerosis (MS) pathogenesis has a double effect: early on during the onset of the immune attack and later for the CNS self-sustained ‘inside-out’ demyelination and neurodegeneration processes. This review presents the characteristics of BBB malfunction in MS but mostly highlights current developments regarding the impairment of the neurovascular unit (NVU) and the metabolic and mitochondrial dysfunctions of the BBB’s endothelial cells. The hypoxic hypothesis is largely studied and agreed upon recently in the pathologic processes in MS. Hypoxia in MS might be produced per se by the NVU malfunction or secondary to mitochondria dysfunction. We present three different but related terms that denominate the ongoing neurodegenerative process in progressive forms of MS that are indirectly related to BBB disruption: progression independent of relapses, no evidence of disease activity and smoldering demyelination or silent progression. Dimethyl fumarate (DMF), modulators of S1P receptor, cladribine and laquinimode are DMTs that are able to cross the BBB and exhibit beneficial direct effects in the CNS with very different mechanisms of action, providing hope that a combined therapy might be effective in treating MS. Detailed mechanisms of action of these DMTs are described and also illustrated in dedicated images. With increasing knowledge about the involvement of BBB in MS pathology, BBB might become a therapeutic target in MS not only to make it impenetrable against activated immune cells but also to allow molecules that have a neuroprotective effect in reaching the cell target inside the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312 · cited 4×
“Perivascular astrogliosis and the retraction of astrocytic end-feet contribute to the exposure of the central compartment to cells and substances from the bloodstream [9,11].”
BackgroundInfluentialA blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B., & Prat, A. (2007) · Nature Medicine · doi:10.1038/nm1651 · Cited by 1,759 · cited 1×
“As an example, the Th 17 cells, with the high expression of granzyme B, attain increased migratory capacity on arrival in the CNS and continue to stimulate demyelination and extensive axonal degeneration through the following: (1) direct interaction with myelin oligodendrocyte glycoprotein; (2) Th 17 cells secretion o…”
BackgroundThe relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1716 · Cited by 1,206
Inflammatory cortical demyelination in early multiple sclerosis.
Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100648 · Cited by 1,103
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942
How leukocytes cross the vascular endothelium
Vestweber, D. (2015) · Nature Reviews Immunology · doi:10.1038/nri3908 · Cited by 858
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796 · cited 2×
“S1P3 receptors and by the up-regulation of BNDF expression, with neuroprotective effects [113,116].”
BackgroundClaudin-5: gatekeeper of neurological function
Greene, C., Hanley, N., & Campbell, M. (2019) · Fluids and Barriers of the CNS · doi:10.1186/s12987-019-0123-z · Cited by 583
CSF, blood-brain barrier, and brain drug delivery
Pardridge, W. M. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1171315 · Cited by 508 · cited 1×
“The highly selective BBB permeability would purposely impair even the direct intrathecal administration of immunomodulatory agents due to the uneven distribution and subsequent metabolisation of the subependymal substrate and the parenchyma [155].”
BackgroundTargeting and Crossing the Blood-Brain Barrier with Extracellular Vesicles
Saint-Pol, J., Gosselet, F., Duban-Deweer, S., Pottiez, G., & Karamanos, Y. (2020) · Cells · doi:10.3390/cells9040851 · Cited by 503
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459 · cited 1×
“In order for a DMT to be efficient in secondary progressive MS, it has to pass the BBB in its active form and directly exert its action upon the CNS inflammatory cells (microglia, astrocyte, oligodendrocyte) [163].”
BackgroundBlood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405 · cited 1×
“Novel gene therapies are based on proposed associations between various viral genes and autologous stem cells, such as lentivirus and adeno-associated virus genes, but the associated risks, such as leukemia and uneven distribution, greatly limit the practical application of these methods [156].”
BackgroundRole of the Blood–Brain Barrier in Multiple Sclerosis
Ortiz, G. G., Pacheco-Moisés, F. P., Macías-Islas, M. Á., Flores-Alvarado, L. J., Mireles-Ramírez, M. A., González-Renovato, E. D., Hernández-Navarro, V. E., Sánchez-López, A. L., & Alatorre-Jiménez, M. A. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.11.013 · Cited by 373 · cited 8×
“In response to the serum of RRMS patients, the mitochondria become significantly hyperpolarised–a phenomenon that may be an origin of ROS [6,9,40].”
BackgroundInfluentialHaseloff, R. F., Dithmer, S., Winkler, L., Wolburg, H., & Blasig, I. E. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.11.004 · Cited by 353
Applications of nanotechnology in drug delivery to the central nervous system
Saeedi, M., Eslamifar, M., Khezri, K., & Dizaj, S. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.133 · Cited by 342
Marchetti, L., & Engelhardt, B. (2020) · Vascular Biology · doi:10.1530/vb-19-0033 · Cited by 304
Lopes Pinheiro, M. A., Kooij, G., Mizee, M. R., Kamermans, A., Enzmann, G., Lyck, R., Schwaninger, M., Engelhardt, B., & de Vries, H. E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.018 · Cited by 247
Vascular aspects of multiple sclerosis
D'haeseleer, M., Cambron, M., Vanopdenbosch, L., & De Keyser, J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70105-3 · Cited by 241
Kappos, L., Fox, R. J., Burcklen, M., Freedman, M. S., Havrdová, E. K., Hennessy, B., Hohlfeld, R., Lublin, F., Montalban, X., Pozzilli, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0405 · Cited by 228
Elkins, J., Veltkamp, R., Montaner, J., Johnston, S. C., Singhal, A. B., Becker, K., Lansberg, M. G., Tang, W., Chang, I., Muralidharan, K., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30357-x · Cited by 224
Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment
Carrithers, M. D., Visintin, I., Kang, S. J., & Janeway, C. A. (2000) · Brain · doi:10.1093/brain/123.6.1092 · Cited by 220
Review: Mitochondria and disease progression in multiple sclerosis
Mahad, D., Lassmann, H., & Turnbull, D. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00987.x · Cited by 193
Leech, S., Kirk, J., Plumb, J., & McQuaid, S. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00781.x · Cited by 137
Gonzalez-Carter, D., Liu, X., Tockary, T. A., Dirisala, A., Toh, K., Anraku, Y., & Kataoka, K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002016117 · Cited by 127
Cramer, S. P., Modvig, S., Simonsen, H. J., Frederiksen, J. L., & Larsson, H. B. W. (2015) · Brain · doi:10.1093/brain/awv203 · Cited by 94
Paintlia, A. S., Paintlia, M. K., Singh, A. K., & Singh, I. (2013) · Glia · doi:10.1002/glia.22537 · Cited by 43
Cited by
Li, J., Wei, Y., Zhang, C., Bi, R., Qiu, Y., Li, Y., & Hu, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020621 · Cited by 85
Rouillard, M. E., Hu, J., Sutter, P. A., Kim, H. W., Huang, J. K., & Crocker, S. J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.833186 · Cited by 35
White Matter in Crisis: Oligodendrocytes and the Pathophysiology of Multiple Sclerosis
García-Domínguez, M. (2025) · Cells · doi:10.3390/cells14181408 · Cited by 13
“These lesions are often accompanied by perivascular infiltration of white blood cells (mainly lymphocytes and monocytes), suggesting a breakdown of the blood–brain barrier (BBB) and entry of autoreactive immune cells into the CNS parenchyma (Figure 1) [19,20].”
Xu, J., Du, Y., Zhu, N., Li, J., Zhang, Y., Zhou, D., & Zhu, S. (2025) · Advanced Science · doi:10.1002/advs.202500443 · Cited by 10
Metadata
- Authors
- Balasa, R., Barcutean, L., Mosora, O., & Manu, D.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-08-04
- Volume
- 22
- Issue
- 16
- Pages
- 8370
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3191624239
- Cited by
- 158
- References
- 28
- FWCI
- 13.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.